在晚期肾细胞癌患者中导航和调整免疫治疗、抗血管生成治疗和联合治疗的护理。
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma.
机构信息
Vanderbilt University Medical Center, Nashville, Tennessee, USA
University of Texas Southwestern Department of Internal Medicine, Dallas, Texas, USA
出版信息
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006361.
Abstract
Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.
摘要
晚期肾细胞癌是一种生物学异质性疾病，有多种治疗选择，主要包括免疫治疗和/或抗血管生成治疗。初始治疗和后续治疗的选择取决于临床和生物学因素。在此，我们将描述如何将最近的数据应用于临床实践。
相似文献
1
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma.在晚期肾细胞癌患者中导航和调整免疫治疗、抗血管生成治疗和联合治疗的护理。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006361.
2
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.纳武利尤单抗治疗晚期肾细胞癌：临床实践考量
Urol Oncol. 2017 Apr;35(4):142-148. doi: 10.1016/j.urolonc.2017.01.017. Epub 2017 Mar 2.
3
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?免疫肿瘤联合治疗中晚期或中高危国际转移性肾细胞癌数据库联盟标准治疗的晚期肾细胞癌患者的真实世界结局：风险组的疗效差异？
Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.
4
Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era.下一步：在当代转移性肾细胞癌中进行测序治疗。
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-11. doi: 10.1200/EDBK_320785.
5
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).癌症免疫治疗学会关于免疫治疗晚期肾细胞癌（RCC）的共识声明。
J Immunother Cancer. 2019 Dec 20;7(1):354. doi: 10.1186/s40425-019-0813-8.
6
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review.转移性肾细胞癌的血管生成和免疫途径：拮抗范式还是同一枚硬币的两面？GIANUS 综述。
Crit Rev Oncol Hematol. 2019 Jul;139:149-157. doi: 10.1016/j.critrevonc.2018.07.009. Epub 2018 Aug 1.
7
Will the dark sky over advanced renal cell carcinoma soon become brighter?晚期肾细胞癌的黑暗天空会很快放晴吗？
Eur J Cancer. 2005 Jun;41(9):1246-53. doi: 10.1016/j.ejca.2004.11.025.
8
New drug therapies for advanced renal cell carcinoma.晚期肾细胞癌的新药疗法
Expert Rev Anticancer Ther. 2007 Jan;7(1):57-71. doi: 10.1586/14737140.7.1.57.
9
Selecting targeted therapies for patients with renal cell carcinoma.为肾细胞癌患者选择靶向治疗药物。
J Natl Compr Canc Netw. 2011 Sep 1;9(9):997-1006; quiz 1007. doi: 10.6004/jnccn.2011.0084.
10
Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.肉瘤样肾细胞癌患者 - 重新定义一线治疗：免疫检查点抑制剂随机临床试验的荟萃分析。
Eur J Cancer. 2020 Sep;136:195-203. doi: 10.1016/j.ejca.2020.06.008. Epub 2020 Jul 23.
引用本文的文献
1
Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell Carcinoma.立体定向放射治疗用于治疗肾细胞癌腺性转移灶
Adv Radiat Oncol. 2025 Jun 13;10(9):101835. doi: 10.1016/j.adro.2025.101835. eCollection 2025 Sep.
2
Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma.转移性肾癌：转移部位重要吗？迈向转移性肾细胞癌的个性化治疗。
Biomedicines. 2024 May 16;12(5):1111. doi: 10.3390/biomedicines12051111.
3
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.通过启动子超甲基化沉默基因塑造透明细胞肾细胞癌的肿瘤微环境和免疫治疗抵抗性。
Cell Rep Med. 2023 Nov 21;4(11):101287. doi: 10.1016/j.xcrm.2023.101287. Epub 2023 Nov 14.
本文引用的文献
1
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肉瘤样肾细胞癌患者一线治疗的长期结局。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005445.
2
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).纳武利尤单抗单药及挽救性纳武利尤单抗/伊匹木单抗治疗初治晚期透明细胞肾细胞癌（HCRN GU16-260-队列 A）的 II 期研究。
J Clin Oncol. 2022 Sep 1;40(25):2913-2923. doi: 10.1200/JCO.21.02938. Epub 2022 Apr 20.
3
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.纳武利尤单抗联合伊匹单抗对比舒尼替尼治疗晚期肾细胞癌患者的条件生存和长期疗效。
Cancer. 2022 Jun 1;128(11):2085-2097. doi: 10.1002/cncr.34180. Epub 2022 Apr 5.
4
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features.一线免疫检查点抑制剂治疗具有肉瘤样特征的晚期或转移性肾细胞癌。
Cancer Treat Rev. 2022 Apr;105:102374. doi: 10.1016/j.ctrv.2022.102374. Epub 2022 Mar 10.
5
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer.帕博利珠单抗与高剂量白细胞介素-2联合治疗（连续5天给药方案）用于转移性透明细胞肾细胞癌的治疗
Clin Genitourin Cancer. 2022 Jun;20(3):252-259. doi: 10.1016/j.clgc.2022.01.010. Epub 2022 Feb 9.
6
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.贝伐珠单抗治疗 von Hippel-Lindau 病相关肾细胞癌
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
7
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.用贝佐蒂凡抑制肾细胞癌中的缺氧诱导因子-2α：一项1期试验及生物标志物分析
Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22.
8
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
9
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
10
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.帕博利珠单抗单药作为晚期透明细胞肾细胞癌患者一线治疗的开放标签、单臂II期研究。
J Clin Oncol. 2021 Mar 20;39(9):1020-1028. doi: 10.1200/JCO.20.02363. Epub 2021 Feb 2.
Zotero 插件